HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.

AuthorsIrene Prediletto, Sarah A Farag, Ulrike Bacher, Barbara Jeker, Behrouz Mansouri Taleghani, Rachel Brégy, Thilo Zander, Daniel Betticher, Thomas Egger, Urban Novak, Thomas Pabst
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 54 Issue 12 Pg. 1923-1925 (12 2019) ISSN: 1476-5365 [Electronic] England
PMID30890768 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Bendamustine Hydrochloride
Topics
  • Antineoplastic Agents, Alkylating (adverse effects, pharmacology, therapeutic use)
  • Bendamustine Hydrochloride (adverse effects, pharmacology, therapeutic use)
  • Female
  • Humans
  • Incidence
  • Kidney (drug effects)
  • Lymphoma (drug therapy)
  • Male
  • Multiple Myeloma (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: